Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01162551 · ClinicalTrials.gov registry record · Phase 2

Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

A Phase 2 study, sponsored by Children's Hospital of Philadelphia.

Completed
Registry status
Phase 2
Development phase
5
Enrollment target

NCT01162551 is a Phase 2 study that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01162551, a Phase 2 study, has completed, sponsored by Children's Hospital of Philadelphia.

COMPLETED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

This is a phase 2 study looking at efficacy and toxicity of oral sirolimus in combination with oral methotrexate in children with refractory/relapsed ALL or NHL. Secondary objectives include characterizing the trough levels produced by administration of oral sirolimus in children with refractory/relapsed ALL/NHL and to evaluate the effect of sirolimus on intracellular targets related to mTOR inhibition.

Interventions

  • DRUG Sirolimus and Methotrexate

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2010-05
Est. Completion 2017-02
Phase Phase 2

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT01162551

The ClinicalTrials.gov registry entry for NCT01162551 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Sirolimus and Methotrexate is the first listed.

NCT01162551 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01162551 about?

NCT01162551 is a clinical study titled "Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma". This is a phase 2 study looking at efficacy and toxicity of oral sirolimus in combination with oral methotrexate in children with refractory/relapsed ALL or NHL. Secondary objectives include characterizing the trough levels produced by administration of oral sirolimus in children with refractory/re...

What is the current status of trial NCT01162551?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-05. Estimated completion is 2017-02.

What interventions are being tested in trial NCT01162551?

The interventions under investigation include: Sirolimus and Methotrexate (DRUG).

Who is sponsoring clinical trial NCT01162551?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.